Bipolar Disorder denials in California external review
In the California DMHC record, independent physician reviewers decided 433 published external-review cases involving bipolar disorderand overturned the plan’s denial in 59.1%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for bipolar disorder
| Treatment | Decisions | Overturned |
|---|---|---|
| Residential Treatment Center | 119 | 74.8% |
| Residential Treatment | 37 | 59.5% |
| Partial Hospitalization Program | 23 | 69.6% |
| Intensive Outpatient Program | 18 | 77.8% |
| TMS | 15 | 6.7% |
| Residential Treatment Center Admission | 15 | 53.3% |
| Inpatient Psychiatric Hospitalization | 14 | 71.4% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 403 | 62.5% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 26 | 3.8% |
Urgent Care Expedited reviews, decided in days rather than weeks. | 4 | 75% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement for residential treatment center (RTC) services, specifically ASAM level 3.1. Per the American Society of Addiction Medicine (ASAM) criteria, this patient meets Level 3.1 criteria for RTC services for the time period under review. The ASAM criteria focus on six dimensions to determine the appropriate level of care, which includes: (1)intoxication and associated risk, withdrawal and associated risks, and addiction medication needs; (2)biomedical conditions including physical health concerns and pregnancy-related concerns; (3)psychiatric and cognitive conditions and history including active psychiatric symptoms and persistent disability; (4)substance-use-related risks including the likelihood of engaging in risky substance use and the likelihood of engaging in risk…
Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement and prospective authorization and coverage for residential treatment center (RTC) services (ASAM 3.1). Per the American Society of Addiction Medicine (ASAM) criteria, this patient meets Level 3.1 criteria for RTC services for the time period under review. The ASAM criteria focus on six dimensions to determine the appropriate level of care, which includes: (1) intoxication and associated risk, withdrawal and associated risks, and addiction medication needs; (2) biomedical conditions including physical health concerns and pregnancy-related concerns; (3) psychiatric and cognitive conditions and history including active psychiatric symptoms and persistent disability; (4) substance-use-related risks including the likelihood of engaging in risky substance use and the likelihood of engaging in risky substance use…
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient has requested authorization for residential treatment center (RTC) services (ASAM 3.5) that include treatment for compulsive sexual behaviors with a multidisciplinary team which includes certified sex addition therapists (CSAT). For Dimension 1, In this case, the patient will be going into RTC treatment following prior detoxification. The patient is experiencing or anticipated to imminently experience mild to moderate signs and/or symptoms of intoxication that can be addressed in any level of care as needed and thus does not require a medically managed addiction treatment program for intoxication management.
Physician 1: The patient is a 39-year-old man with long history of depressive disorder resistant to multiple antidepressant medications and some medication combinations. He has had multiple psychiatric hospitalizations for treatment of depression and associated suicidal ideation. ECT treatments have not been of consistent benefit, both bilateral and unilateral series with monthly maintenance. A review of documents seems to indicate that mono-amine oxidase inhibitors (MAOI) are the only class of antidepressant medications that have not been utilized. The patient has requested authorization for vagus nerve stimulation (VNS) therapy to treat his depression.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
A diagnosis does not by itself establish treatment intensity. See the separate record for residential, PHP, IOP, inpatient, and withdrawal-management denials: behavioral-health level-of-care evidence guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving bipolar disorder, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY